IDEAYA Biosciences Inc. (IDYA)
IDEAYA Biosciences Statistics
Share Statistics
IDEAYA Biosciences has 87.54M shares outstanding. The number of shares has increased by 15.66% in one year.
Shares Outstanding | 87.54M |
Shares Change (YoY) | 15.66% |
Shares Change (QoQ) | 1.28% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 80.84M |
Failed to Deliver (FTD) Shares | 68 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 9.95M, so 11.36% of the outstanding shares have been sold short.
Short Interest | 9.95M |
Short % of Shares Out | 11.36% |
Short % of Float | 12.65% |
Short Ratio (days to cover) | 10.6 |
Valuation Ratios
The PE ratio is -7.65 and the forward PE ratio is -6.57. IDEAYA Biosciences's PEG ratio is -0.11.
PE Ratio | -7.65 |
Forward PE | -6.57 |
PS Ratio | 299.88 |
Forward PS | 2.6 |
PB Ratio | 1.98 |
P/FCF Ratio | -8.35 |
PEG Ratio | -0.11 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for IDEAYA Biosciences.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.97, with a Debt / Equity ratio of 0.02.
Current Ratio | 14.97 |
Quick Ratio | 14.97 |
Debt / Equity | 0.02 |
Debt / EBITDA | -0.06 |
Debt / FCF | -0.08 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $53.44K |
Profits Per Employee | $-2.1M |
Employee Count | 131 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -52.75% in the last 52 weeks. The beta is 0.51, so IDEAYA Biosciences's price volatility has been higher than the market average.
Beta | 0.51 |
52-Week Price Change | -52.75% |
50-Day Moving Average | 18.41 |
200-Day Moving Average | 28.21 |
Relative Strength Index (RSI) | 58.63 |
Average Volume (20 Days) | 1.19M |
Income Statement
In the last 12 months, IDEAYA Biosciences had revenue of 7M and earned -274.48M in profits. Earnings per share was -3.36.
Revenue | 7M |
Gross Profit | 7M |
Operating Income | -326.98M |
Net Income | -274.48M |
EBITDA | -326.98M |
EBIT | -326.98M |
Earnings Per Share (EPS) | -3.36 |
Balance Sheet
The company has 84.38M in cash and 19.17M in debt, giving a net cash position of 65.21M.
Cash & Cash Equivalents | 84.38M |
Total Debt | 19.17M |
Net Cash | 65.21M |
Retained Earnings | -622.84M |
Total Assets | 1.12B |
Working Capital | 643.64M |
Cash Flow
In the last 12 months, operating cash flow was -247.58M and capital expenditures -3.86M, giving a free cash flow of -251.44M.
Operating Cash Flow | -247.58M |
Capital Expenditures | -3.86M |
Free Cash Flow | -251.44M |
FCF Per Share | -3.08 |
Margins
Gross margin is 100%, with operating and profit margins of -4671.07% and -3921.1%.
Gross Margin | 100% |
Operating Margin | -4671.07% |
Pretax Margin | -3921.1% |
Profit Margin | -3921.1% |
EBITDA Margin | -4671.07% |
EBIT Margin | -4671.07% |
FCF Margin | -3592.01% |
Dividends & Yields
IDYA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for IDYA is $53, which is 181.5% higher than the current price. The consensus rating is "Buy".
Price Target | $53 |
Price Target Difference | 181.5% |
Analyst Consensus | Buy |
Analyst Count | 13 |
Scores
Altman Z-Score | 13.65 |
Piotroski F-Score | 2 |